Skip to main content

Clinical Trials Using Fludeoxyglucose F-18

Review the clinical trials studying fludeoxyglucose f-18 on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 26-50 of 80

18F-Fluciclovine PET/CT in Multiple Myeloma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Radiotherapy Dose De-escalation for the Treatment of HPV-Associated Cancers of the Oropharynx
Status: Active
Location: Duke University Medical Center, Durham, North Carolina
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Zanzalintinib as Maintenance Therapy after Chemotherapy for the Treatment of High Grade Neuroendocrine Tumors
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Radiation Therapy in Reduced Dose and Hypofractionated Schedule after Trans-Oral Robotic Surgery to Improve Quality of Life in Patients with Intermediate Risk HPV-Mediated Oropharyngeal Squamous Cell Carcinoma
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Elranatamab as Maintenance Therapy after Ciltacabtagene-Autoleucel for the Treatment of High Risk Relapsed Refractory Multiple Myeloma
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Circulating Tumor DNA to Determine Early Switch From First-Line mFOLFIRINOX to Second-Line Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma
Status: Active
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
An Attenuated Schedule of the Dara-RVd Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Epcoritamab with Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Split Course Adaptive Radiation Therapy and Immunotherapy with or without Chemotherapy for the Treatment of Stage IV or Locally Advanced Lung Cancer, SiCARIO Study
Status: Active
Location: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
A Study of Repotrectinib in Combination with Chemotherapy in Children and Young Adults with Solid Tumor Cancer
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
REGN5678 before Surgery for Treating Patients with High-Risk Localized Prostate Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Tafasitamab, Retifanlimab, and Rituximab in Combination with Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas
Status: Active
Location: 3 locations
Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma with an EGFR Amplification or Mutation, ERAS801-SARG Trial
Status: Active
Location: 2 locations
Giving NT-I7 after Standard CAR T-Cell Therapy for the Treatment of Recurrent or Refractory Large B-Cell Lymphoma
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive, IDH-Wildtype, Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
REGN5678 and Cemiplimab for the Treatment of Patients with Metastatic Castration Resistant Prostate Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Tumor Infiltrating Lymphocytes for the Treatment of Children with High Risk Solid Tumors
Status: Active
Location: Johns Hopkins All Children's Hospital, Saint Petersburg, Florida
Ruxolitinib in Combination with CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Spectroscopic MRI-Guided Proton Radiation Therapy and Bevacizumab for the Treatment of Recurrent Glioblastoma
Status: Active
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
Telaglenastat and Chemoradiotherapy for the Treatment of Advanced Cervical Cancer
Status: Approved
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Immunotherapy (Pembrolizumab) and Chemotherapy (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) with ctDNA-Guided Consolidation for the Treatment of Relapsed or Refractory Classic Hodgkin Lymphoma
Status: Approved
Location: University of California San Francisco, San Francisco, California